Does treating with anti–PD-1 to improve glomerular health come without a cost?

Kenar D. Jhaveri; Abhijat Kitchlu; Ala Abudayyeh

doi:10.1172/JCI164747

Does treating with anti–PD-1 to improve glomerular health come without a cost?

Kenar D. Jhaveri, Abhijat Kitchlu, Ala Abudayyeh

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Article number	JCI164747
Journal	Journal of Clinical Investigation
Volume	132
Issue number	22
DOIs	https://doi.org/10.1172/JCI164747
State	Published - Nov 15 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1172/JCI164747

Cite this

@article{7b2bd3849ac84d8b8ee2ab8a03d74ae2,

title = "Does treating with anti–PD-1 to improve glomerular health come without a cost?",

author = "Jhaveri, {Kenar D.} and Abhijat Kitchlu and Ala Abudayyeh",

note = "Funding Information: Conflict of interest: KDJ serves as a consultant for PMV Pharmaceuticals, Secretome, George Clinicals, and Calliditas. KDJ is the current copresident of the American Society of Oncone-phrology (ASON) and is a paid contributor to UpToDate.com. AA is a founding member of the ASON. AK administers funds from Amgen Inc. and Jassen Inc. to support the University Health Network Onco-Nephrology Fellowship. AK is a founding member of the ASON.",

year = "2022",

month = nov,

day = "15",

doi = "10.1172/JCI164747",

language = "English (US)",

volume = "132",

journal = "Journal of Clinical Investigation",

issn = "0021-9738",